QuiaPEG

Newsroom

Dec 10, 2018

QuiaPEG Pharmaceuticals Holding AB (publ) develops improved and patentable versions of clinically validated or approved drugs, so called biobetters. This is based on the company's proprietary patent-protected technology platform, Uni-Qleaver®, which allows a chosen release time for the drug through a controllable chemical coupling unit. After receiving positive pre- clinical trial results for QPG-1029, QuiaPEG today announces that it has signed a Material Transfer Agreement (MTA) with an Asian pharmaceutical company regarding the QPG-1029 drug project (peg-liraglutid), which has blockbuster1 potential in the indications diabetes and overweight.

Download press release (PDF)
Contact
QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 54 Uppsala
Sweden
+46 (0) 70 693 12 53
info@quiapeg.com

User terms & privacy policy
Send a message